Critical Comparison: TG Therapeutics (TGTX) & The Competition

TG Therapeutics (NASDAQ:TGTX) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare TG Therapeutics to similar businesses based on the strength of its analyst recommendations, earnings, profitability, risk, valuation, institutional ownership and dividends.

Valuation and Earnings

This table compares TG Therapeutics and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
TG Therapeutics	$799.54 million	$447.18 million	21.84
TG Therapeutics Competitors	$728.25 million	$12.25 million	-15.19

TG Therapeutics has higher revenue and earnings than its peers. TG Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares TG Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	55.22%	73.49%	34.14%
TG Therapeutics Competitors	-12,357.18%	-197.96%	-30.56%

Volatility & Risk

TG Therapeutics has a beta of 1.89, meaning that its stock price is 89% more volatile than the S&P 500. Comparatively, TG Therapeutics’ peers have a beta of 1.15, meaning that their average stock price is 15% more volatile than the S&P 500.

Insider and Institutional Ownership

58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 8.9% of TG Therapeutics shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for TG Therapeutics and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	1	1	6	1	2.78
TG Therapeutics Competitors	9838	15122	45436	1587	2.54

TG Therapeutics presently has a consensus price target of $63.00, suggesting a potential upside of 5.30%. As a group, “Biotechnology” companies have a potential upside of 103.01%. Given TG Therapeutics’ peers higher probable upside, analysts plainly believe TG Therapeutics has less favorable growth aspects than its peers.

Summary

TG Therapeutics beats its peers on 11 of the 13 factors compared.

About TG Therapeutics

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.